<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973515</url>
  </required_header>
  <id_info>
    <org_study_id>PB-201</org_study_id>
    <nct_id>NCT03973515</nct_id>
  </id_info>
  <brief_title>Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Three Dose Levels of the Investigational Drug (PB-201) in Drug-naive Adult Subjects With Type 2 Diabetes Mellitus as Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PegBio Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PegBio Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This crossover study investigates the safety, tolerability, pharmacokinetics (PK)
      ,pharmacodynamics (PD) effect of three dose levels of PB-201,and characterizes the PK profile
      of a prominent des-methyl metabolite of PB-201(WI-0800), following dosing of three dose
      levels of PB-201 in drug-naive Chinese adult subjects with Type 2 diabetes mellitus (T2DM) as
      monotherapy.

      There were 7 days separating 4 treatment periods and at least 7-day washout (but not
      exceeding 14 days) between dosing in 4 periods with 3 dose levels of PB-201 and placebo.
      Three dose levels of PB-201 are: split dose regimen of 50 mg 30 minutes before morning meal
      plus 50 mg 30 minutes before lunch at approximately 3.5 hours after morning dose, and split
      dose regimen of 100 mg 30 minutes before morning meal plus 100 mg 30 minutes before lunch at
      approximately 3.5 hours after morning dose, and split dose regimen of 150 mg 30 minutes
      before morning meal plus 100 mg 30 minutes before lunch at approximately 3.5 hours after
      morning dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2019</start_date>
  <completion_date type="Actual">December 19, 2019</completion_date>
  <primary_completion_date type="Actual">December 19, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to peak(Tmax)</measure>
    <time_frame>9 days</time_frame>
    <description>hour</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>9 days</time_frame>
    <description>ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>9 days</time_frame>
    <description>ngâ€¢hr/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change for fasting plasma glucose (FPG)</measure>
    <time_frame>8days</time_frame>
    <description>The change from baseline value (day 0) to the last dose of drug in this period (day 7) compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change for postprandial plasma glucose (PPG)</measure>
    <time_frame>8 days</time_frame>
    <description>The change from baseline value (day 0) to the last dose of drug in this period (day 7) compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change for plasma C-peptide</measure>
    <time_frame>8 days</time_frame>
    <description>The change from baseline value (day 0) to the last dose of drug in this period (day 7) compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change for plasma insulin</measure>
    <time_frame>8 days</time_frame>
    <description>The change from baseline value (day 0) to the last dose of drug in this period (day 7) compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>PB-201 50/50mg by mouth,every morning and noon for 7 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PB-201 100/50mg by mouth,every morning and noon for 7 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PB-201 100/100mg by mouth,every morning and noon for 7 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glucokinase activator</intervention_name>
    <description>PB-201 is a kind of dual and partial GKA</description>
    <arm_group_label>PB-201 100/100mg by mouth,every morning and noon for 7 days</arm_group_label>
    <arm_group_label>PB-201 100/50mg by mouth,every morning and noon for 7 days</arm_group_label>
    <arm_group_label>PB-201 50/50mg by mouth,every morning and noon for 7 days</arm_group_label>
    <other_name>PB-201</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral tablet</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>PB-201 Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Glycosylated hemoglobin (HbA1c) 7.5%-11% at screening, and 7.0%-10.0%
             pre-randomization

          2. FPG 7.0 mmol/L-11.0mmol/L at screening and pre-randomization

          3. Body mass index (BMI) 18.5 and-35.0 kg/m2 at screening

          4. Antidiabetics-naive within 2 months before screening

        Exclusion Criteria:

          1. Diagnosis of type 1 diabetes mellitus or secondary forms of diabetes

          2. History of febrile illness within 5 days prior to dosing

          3. Medical history of myocardial infarction, angina/unstable angina, coronary
             revascularization, stroke or transient ischemic attack

          4. Any medical history or current clinical evidence of congestive heart failure, New York
             Heart Association (NYHA) Functional Classification, Classes II-IV

          5. Episode(s) of hypoglycemia adverse events (HAE) of 'severe' intensity prior to
             screening; either:

               1. &gt;1 in the previous 3 months; or

               2. &gt;2 in the previous 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HaiYan Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>June 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucokinase activator(GKA)</keyword>
  <keyword>hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

